Literature DB >> 14999636

Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic.

Antonio Urbina1, Kristina Jones.   

Abstract

The use of the recreational drug crystal methamphetamine among younger homosexual men is expanding, and with it, unsafe sex behaviors that increase the transmission of human immunodeficiency virus (HIV). This article reviews available literature on the medical and psychiatric morbidities associated with methamphetamine abuse in HIV-infected patients. Medical complications include hypertension, hyperthermia, rhabdoymyolysis, and stroke. One fatal case of ingestion of methamphetamine with HIV medication has been documented. Two fatal cases of ingestion of HIV medication with the amphetamine analogue n-methyl-3,4 methylenedioxymethamphetamine (MDMA, or "ecstasy") have also been reported. Some molecular researchers suggest that dopaminergic systems are vulnerable to the combined neurotoxicity of HIV infection and methamphetamine. Population surveys indicate high rates of HIV infection among methamphetamine abusers and high rates of unprotected anal intercourse during drug intoxication. Intoxication can sometimes produce paranoia, auditory hallucinations, and, occasionally, violent behavior. Amphetamine withdrawal commonly results in symptoms of depression. Methamphetamine is a new challenge related to treatment and prevention of HIV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999636     DOI: 10.1086/381975

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  57 in total

1.  Associations between methamphetamine use and HIV among men who have sex with men: a model for guiding public policy.

Authors:  Steven Shoptaw; Cathy J Reback
Journal:  J Urban Health       Date:  2006-11       Impact factor: 3.671

Review 2.  Drugs of abuse, immune modulation, and AIDS.

Authors:  Guy A Cabral
Journal:  J Neuroimmune Pharmacol       Date:  2006-06-28       Impact factor: 4.147

3.  Predictors of methamphetamine injection in out-of-treatment IDUs.

Authors:  Karen F Corsi; Carol F Kwiatkowski; Robert E Booth
Journal:  Subst Use Misuse       Date:  2009       Impact factor: 2.164

Review 4.  The methamphetamine epidemic: implications for HIV prevention and treatment.

Authors:  Grant Colfax; Steven Shoptaw
Journal:  Curr HIV/AIDS Rep       Date:  2005-11       Impact factor: 5.071

5.  Binge use and sex and drug use behaviors among HIV(-), heterosexual methamphetamine users in San Diego.

Authors:  W Susan Cheng; Richard S Garfein; Shirley J Semple; Steffanie A Strathdee; James K Zians; Thomas L Patterson
Journal:  Subst Use Misuse       Date:  2010       Impact factor: 2.164

6.  Antiretrovirals, Methamphetamine, and HIV-1 Envelope Protein gp120 Compromise Neuronal Energy Homeostasis in Association with Various Degrees of Synaptic and Neuritic Damage.

Authors:  Ana B Sanchez; Giuseppe P Varano; Cyrus M de Rozieres; Ricky Maung; Irene C Catalan; Cari C Dowling; Natalia E Sejbuk; Melanie M Hoefer; Marcus Kaul
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

7.  Body mass index, depression and sexual transmission risk behaviors among HIV-positive MSM.

Authors:  Aaron J Blashill; Conall O'Cleirigh; Kenneth H Mayer; Brett M Goshe; Steven A Safren
Journal:  AIDS Behav       Date:  2012-11

8.  Methamphetamine enhances HIV infection of macrophages.

Authors:  Hao Liang; Xu Wang; Hui Chen; Li Song; Li Ye; Shi-Hong Wang; Yan-Jian Wang; Lin Zhou; Wen-Zhe Ho
Journal:  Am J Pathol       Date:  2008-05-05       Impact factor: 4.307

9.  Methamphetamine use and malnutrition among street-involved youth.

Authors:  Dan Werb; Thomas Kerr; Ruth Zhang; Julio S G Montaner; Evan Wood
Journal:  Harm Reduct J       Date:  2010-03-08

Review 10.  Development of active and passive human vaccines to treat methamphetamine addiction.

Authors:  W Brooks Gentry; Daniela Rüedi-Bettschen; S Michael Owens
Journal:  Hum Vaccin       Date:  2009-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.